Zydus Lifesciences Gains 1.91%: 5 Key Factors Driving This Week’s Mixed Momentum

9 February: Bullish Surge in Derivatives and Price

On 9 Feb 2026, Zydus Lifesciences demonstrated strong bullish momentum, closing at Rs.923.10, a 3.97% increase from the previous close. This outperformance was supported by a significant 43.9% surge in open interest in the derivatives segment, rising from 16,741 to 24,091 contracts. The total derivatives turnover was substantial, with futures valued at approximately ₹51,590 lakhs and options at ₹45,625 crores in notional value. The stock outpaced the Pharmaceuticals & Biotechnology sector’s 1.56% gain and the Sensex’s 1.04% rise, signalling robust investor interest.

Technically, the stock traded above its 5-day, 20-day, and 50-day moving averages, indicating short- to medium-term bullish momentum, although it remained below longer-term averages. Delivery volumes declined by 16.22% compared to the 5-day average, suggesting that while derivatives activity was strong, actual shareholding participation was subdued. This divergence points to speculative or hedging activity rather than outright accumulation.

10 February: Bearish Signals Amid Rising Open Interest

The following day, 10 Feb, the stock reversed sharply, falling 3.89% to close at Rs.887.20. Despite the price decline, open interest surged again by 33.1%, from 23,796 to 31,670 contracts, accompanied by a total volume of 61,051 contracts. This increase in open interest amid falling prices typically indicates new short positions or liquidation of longs. The stock underperformed both its sector, which declined marginally by 0.11%, and the Sensex, which gained 0.25%.

Technical indicators showed the stock trading below all key moving averages, confirming a sustained downtrend. Delivery volume on 9 Feb had surged by 68.58%, reflecting increased investor participation despite price weakness. The mixed signals suggest a market positioning shift towards bearishness, with traders anticipating further downside or hedging against volatility.

11 February: Mild Recovery Amid Mixed Technical Signals

On 11 Feb, Zydus Lifesciences rebounded modestly, gaining 1.22% to close at Rs.898.05. The stock’s technical momentum was mixed, with indicators signalling a transition from bearish to mildly bearish trends. The MACD remained bearish on the weekly chart but was mildly bearish monthly, while RSI readings were neutral. Bollinger Bands suggested elevated volatility, and moving averages hovered near resistance levels.

Despite the recovery, the stock remained below longer-term moving averages, indicating that a sustained bullish trend had yet to be confirmed. The mixed technical landscape reflected investor caution amid ongoing sectoral headwinds and stock-specific factors.

12 February: Price Gains Despite Broader Market Weakness

On 12 Feb, the stock advanced 2.53% to Rs.920.80, outperforming the Sensex which declined 0.56%. This gain was supported by improved technical momentum, though the overall trend remained mildly bearish. The stock traded near the lower Bollinger Band on weekly charts, suggesting potential support. Volume remained moderate, and technical oscillators such as KST and Dow Theory presented mixed signals.

13 February: Week Ends on a Mixed Note

The week closed on 13 Feb with a 1.73% decline to Rs.904.85 amid mixed technical momentum. The stock’s technical trend shifted subtly from bearish to mildly bearish, with daily gains of 2.22% earlier in the session offset by late profit-taking. MACD and KST indicators remained bearish weekly but mildly bearish monthly, while RSI stayed neutral. On-Balance Volume showed a mildly bullish weekly trend but mildly bearish monthly, reflecting volume-price divergence.

Relative to the Sensex, Zydus Lifesciences outperformed in the short term, with weekly and monthly returns exceeding the benchmark despite longer-term underperformance. The Mojo Score remained at 48.0 with a Sell grade, reflecting cautious analyst sentiment amid technical and fundamental uncertainties.

Weekly Price Performance Comparison

Key Takeaways

Positive Signals: The stock outperformed the Sensex by 2.45% over the week, demonstrating resilience amid broader market weakness. Significant open interest surges on 9 and 10 Feb indicate strong derivatives market interest, with initial bullish positioning followed by increased bearish bets. Technical indicators show a transition from bearish to mildly bearish momentum, suggesting potential stabilisation. The stock’s proximity to its 52-week high and strong multi-year returns highlight underlying strength.

Cautionary Signals: Despite short-term gains, the Mojo Score remains at 48.0 with a Sell grade, reflecting analyst caution. Delivery volumes declined on the bullish day, indicating limited accumulation by long-term investors. The stock traded below longer-term moving averages for much of the week, and bearish technical indicators such as MACD and KST persist on weekly charts. The sharp price decline on 10 Feb amid rising open interest suggests increased short positioning and potential volatility ahead.

Conclusion

Zydus Lifesciences Ltd’s week was characterised by mixed momentum and significant derivatives market activity, resulting in a modest 1.91% weekly gain that outperformed the Sensex’s 0.54% decline. The stock’s price action reflected a tug-of-war between bullish positioning early in the week and bearish sentiment midweek, with technical indicators signalling a cautious transition from bearish to mildly bearish trends. Investors should note the divergence between derivatives activity and delivery volumes, as well as the persistent Sell rating, which counsel prudence. Monitoring the stock’s ability to sustain gains above key moving averages and the evolution of open interest will be critical in assessing its near-term trajectory within the Pharmaceuticals & Biotechnology sector.

Unlock special upgrade rates for a limited period. Start Saving Now →